Phase 2 dose-ranging study to evaluate the efficacy and safety of liposomal irinotecan (LY01610) as a second-line treatment for patients with relapsed small cell lung cancer
Authors
Yueyin Pan (ORCID: https://orcid.org/0000-0003-0532-5368)
Phase 2 dose-ranging study to evaluate the efficacy and safety of liposomal irinotecan (LY01610) as a second-line treatment for patients with relapsed small cell lung cancer
Yueyin Pan, Tianyi Gan, Puyuan Xing, Jia Zeng et al.
Citations
4 citations
Journal
EClinicalMedicine
Topics
Lung Cancer Research Studies
Field-Weighted Citation Impact (FWCI)
1.13
article
Phase 2 dose-ranging study to evaluate the efficacy and safety of liposomal irinotecan (LY01610) as a second-line treatment for patients with relapsed small cell lung cancer
Yueyin Pan, Tianyi Gan, Puyuan Xing, Jia Zeng, Minghong Bi, Shan‐Bing Wang, Yuankai Shi, Xiao Ke, Lei Zhang, Yingchun Wang, Biyong Ren, Xicheng Wang, Guang Cheng, Pu Wang, Weidong Li, Jun Guo, Emei Gao, Yong Liu
article en
4 citations
Abstract
No abstract available for this paper.
Publication Tag
EClinicalMedicineVol. 75
Institutions
Hebei Medical University (CN), University of Science and Technology of China (CN), China Pharmaceutical University (CN), Chinese Academy of Medical Sciences & Peking Union Medical College (CN), National Medical Products Administration (CN), Shantou University (CN), Luye Pharma (Germany) (DE), First Affiliated Hospital of Guangzhou Medical University (CN), Xingtai People's Hospital (CN), First Affiliated Hospital of Guangdong Pharmaceutical University (CN), Second Affiliated Hospital of Shantou University Medical College (CN), Chongqing Three Gorges Central Hospital (CN), The Affiliated Yongchuan Hospital of Chongqing Medical University (CN), Xuzhou Central Hospital (CN), Luye Pharma (China) (CN), First Affiliated Hospital of Bengbu Medical College (CN), Guangzhou Medical University Cancer Hospital (CN), Second People’s Hospital of Yibin (CN), Chongqing Three Gorges University (CN), Chongqing Medical University (CN), Guangzhou Medical University (CN)
Funders
Tongji University, Chinese Academy of Medical Sciences, Peking Union Medical College